24/7 Wall Street
07 Feb 2026, 14:03 UTC · 31w ago
Verdict
Headline takes no side. We score HIMS −1.00 across four claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The HHS has referred Hims & Hers to the Department of Justice for potential federal drug law violations.
More negative than 99% of claims this week
The FDA plans to restrict active ingredients in non-approved compounded GLP-1 medications and use enforcement tools including seizures and injunctions.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 98% of claims this week
Hims & Hers projected $725 million in weight-loss revenue for 2025, representing roughly 30% of its total projected guidance of $2.3B to $2.4B.
So whatThe high concentration of projected revenue in the targeted GLP-1 segment means regulatory failure will materially impact total top-line growth.
More negative than 91% of claims this week
Eli Lilly and Novo Nordisk actively lobbied for and welcomed the FDA and HHS actions against compounded GLP-1 competitors.
So whatThe removal of low-cost compounded alternatives reduces price competition and protects the market share of branded pharmaceutical leaders.
More positive than 77% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
Shares plunged 16% following FDA restrictions on compounded GLP-1s and a DOJ referral from HHS.
More positive than 88% of ticker scores this week
The company applauded FDA steps to restrict compounders of its GLP-1 drugs.
More positive than 88% of ticker scores this week
The company welcomed federal crackdowns on compounded alternatives to its branded drug, Wegovy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
2h ago
More positive than 55% of relationship scores this week
[mutual] Hims competes in the GLP-1 weight-loss market against Eli Lilly's branded products.
More positive than 33% of relationship scores this week
[mutual] Both companies provide branded GLP-1 drugs and jointly urged government intervention against compounders.
+25.2%
Price is moving against the score
$28.81 vs $23.02 close before publication (Feb 6) · not market-adjusted
HIMS chart →
